Provided by Tiger Fintech (Singapore) Pte. Ltd.

Irhythm Technologies Inc.

135.76
-1.2400-0.91%
Post-market: 135.760.00000.00%16:34 EDT
Volume:375.51K
Turnover:51.15M
Market Cap:4.33B
PE:-43.27
High:137.67
Open:135.73
Low:135.37
Close:137.00
Loading ...

Company Profile

Company Name:
Irhythm Technologies Inc.
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
2000
Office Location:
699 8th Street,Suite 600,San Francisco,California,United States
Zip Code:
94103
Fax:
- -
Introduction:
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Directors

Name
Position
Abhijit Y. Talwalkar
Chairman of the Board
Quentin S. Blackford
Director, President and Chief Executive Officer
Brian B. Yoor
Independent Director
Bruce G. Bodaken
Independent Director
Cathleen Noel Bairey Merz
Independent Director
Karen Ling
Independent Director
Karen McGinnis
Director
Kevin O'Boyle
Director

Shareholders

Name
Position
Quentin S. Blackford
Director, President and Chief Executive Officer
Daniel G. Wilson
Chief Financial Officer
Marc Rosenbaum
Senior Vice President, Finance and Chief Accounting Officer
Chad Patterson
Chief Commercial Officer
Mervin Smith
Executive Vice President, Business Operations
Minang Turakhia
Chief Medical Officer, Chief Scientific Officer and Executive Vice President, Product Innovation
Patrick M. Murphy
Chief Business Officer and Chief Legal Officer
Sumi Shrishrimal
Executive Vice President and Chief Risk Officer